蛋白 E6, HPV16 (His)

HPV16 E6 is a viral phosphoprotein with oncogenic activity, belonging to the human papillomavirus early protein family. HPV16 E6 activates the cell cycle by releasing E2F through proteasome degradation of pRB. HPV16 E6 can cooperate with E6 to immortalize cells and neutralize the toxicity of E5, while activating the AP-1/NF-κB pathway and downregulating E-cadherin to enhance migration and invasion, making it a core target for cervical cancer. Protein E6, HPV16 (His) is a recombinant HPV E6 protein expressed from E. coli with an N-6*His tag.

HPV16 E6 是一种多功能核磷蛋白，是 HPV16 致癌的关键癌蛋白，属于人乳头瘤病毒早期蛋白家族。HPV16 E6 的 C 端区域含有保守的 Cys-X-X-Cys 基序，可可逆结合 Zn²⁺，稳定蛋白结构。HPV16 E6 的 N 端与腺病毒 E1A 蛋白具有功能相似性，便于与细胞肿瘤抑制因子相互作用^[1][2]。
HPV16 E6 通过 E6 相关蛋白 (E6AP) 与肿瘤抑制蛋白 p53 结合，促进其泛素化蛋白酶体降解，释放转录因子 E2F，激活细胞周期并抑制凋亡。此外，HPV16 E6 与 E7 协同作用使原代人角质形成细胞永生化，并中和 E5 诱导的细胞毒性。HPV16 E6 还能够激活 AP-1 和 NF-κB 信号通路，下调 E-钙粘蛋白表达，通过破坏细胞间连接增强细胞迁移与侵袭能力，干扰细胞骨架重排以促进上皮-间质转化。HPV16 E6 的上游调控因子包括病毒启动子 (如 LCR)；下游靶点包括 p53、E2F、p16 及 E-钙粘蛋白等，参与细胞周期控制和粘附调节。
HPV16 E6 可用于宫颈癌发生发展的作用机制。而全长 E7 蛋白或 E7 展示载体 (如干酪乳杆菌) 在 TC-1 小鼠等动物模型中诱导特异性抗肿瘤免疫，抑制肿瘤生长并提高生存率。HPV16 E6 是 HPV 相关癌症治疗性疫苗的主要靶点。

Protein E6, HPV16 (3 μg 质粒；48 h 或 24 h) 在滋养层和宫颈细胞系中与 E7 共表达时促进细胞生长、中和 E5 诱导的细胞毒性、降低细胞对组织培养塑料和子宫内膜细胞的黏附、增强细胞迁移和侵袭能力、下调 E-钙粘蛋白表达，并激活 AP-1 和 NF-κB 通路^[2]。

Measured in a cell proliferation assay using A549 cells. The ED₅₀  for this effect is <6.8 ng/mL, corresponding to a specific activity is >1.47×10⁵ units/mg.

• 
  Measured in a cell proliferation assay using A549 cells. The ED₅₀  for this effect is 3.586 ng/mL, corresponding to a specific activity is 2.79×10⁵ units/mg.

Virus

E. coli

N-6*His

P03126 (M1-L158)

1489078  [NCBI]

Full Length

MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL

Approximately 21 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from 0.22 μm filtered solution in 10 mM Tris-HCl, 1 mM EDTA, 6% Trehalose, pH 8.0 or 50 mM Tris-HCl, 300 mM NaCl, 200 mM arginine, pH 8.0 or 50 mM Tris-HCl, 200 mM NaCl, 500 mM arginine, pH 8.0.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Androphy EJ, et al. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 1987 Apr;6(4):989-92.  [Content Brief]

  [2]. Boulenouar S, et al. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis. 2010 Mar;31(3):473-80.  [Content Brief]

  [3]. Duerksen-Hughes PJ, et al. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology. 1999 Nov 10;264(1):55-65.  [Content Brief]

  [4]. Hu D, et al. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo. Arch Gynecol Obstet. 2015 Dec;292(6):1345-54.  [Content Brief]